Pacific Edge Appoints Director to US Board
Pacific Edge Appoints Director to US Board ahead of
anticipated Cxbladder launch
Pacific Edge has taken a further significant step in the commercialisation in the United States of its ground breaking cancer diagnostic test, Cxbladder, with a high calibre appointment to its US subsidiary, Pacific Edge Diagnostics USA, PEDUSA Board of Directors.
Bruce Nogales has extensive experience in life sciences in the United States and international markets and joins the governance team for the Pacific Edge US subsidiary, as a non-executive director. PEDUSA, led by Chief Executive Officer Jackie Walker, is in the final stages of gaining regulatory clearance for its purpose built laboratory in Hershey, Pennsylvania ahead of the anticipated launch of Pacific Edge’s Cxbladder in the US market in early 2013.
Pacific Edge Chairman Chris Swann says the Company is delighted to have attracted a nonexecutive director with the biomedical commercialisation experience of Bruce Nogales whose most recent role was as Senior Vice President and General Manager of Talecris Plasma Resources, the largest business segment of the US-based Talecris Biotheraputics group. Bruce has been involved as an executive in several biomedical companies in both the US and Europe. Over the six years with Talecris, Bruce was responsible for designing and launching a new international business platform, including a European distribution network for the group, the establishment of a plasma collection network in the United States and the successful Initial Public Offering (IPO) of Talecris Biotheraputics in 2009. Prior to Talecris, Bruce was senior executive responsible for Aventis Behring’s commercial operations in Asia-Pacific, Latin America and emerging markets.
“Bruce brings to PEDUSA a deep understanding of the requirements for the successful introduction of new medical and biomedical products in the US, largest healthcare market in the world. Based in the US, Jackie Walker and Bruce Nogales in their executive and governance roles respectively, will lead and help govern the roll-out of this exciting new business commercialising Cxbladder in the United States.”
Bruce Nogales joins Chris Swann the Chair of Pacific Edge, the New Zealand based parent, along with David Band a non-executive Director of Pacific Edge and the CEO of Pacific Edge, David Darling on the governance board of PEDUSA.
Cxbladder, a non-invasive test for the, cost effective and accurate detection of the presence of bladder cancer, is the first commercial application for Pacific Edge following 10 years research into genetic markers. The Company has several products in development underpinned by an extensive portfolio of intellectual property. Many of these patents are now issuing in key geographies. Cxbladder is now commercially available to clinicians and physicians in New Zealand and Australia and is expected to be commercially available in Spain and the US early this year 2013.